Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Q2 FY2025 Earnings Presentation

23 slides from Alembic Pharmaceuticals's earnings presentation, Nov 7, 2024

  1. Slide 1: Alembic Pharmaceuticals Limited Investor Presentation Q2FY25

    Alembic Pharmaceuticals Limited Investor Presentation Q2FY25 Nov 07, 2024

  2. Slide 2: Safe Harbour Statement

    Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff

  3. Slide 3: Quarterly Snapshot

    Quarterly Snapshot INR Bn Key Highlights : 3% YoY Revenue R&D India Branded Business : India Branded Business 16.48 6% QoQ 8% of Sales recorded 6% growth with topline of INR 6.09 billion for Q2 FY25. US Generics : Growth of 5% on YoY basis led by market share gain in few selected products, partially

  4. Slide 4: Revenue Snapshot

    Revenue Snapshot INR Bn Business Q2 FY25 Q2 FY24 Y-o-Y Q1 FY25 Q-o-Q H1 FY25 H1 FY24 Y-o-Y Formulations India 6.09 5.77 6% 5.72 7% 11.81 11.01 7% US 4.67 4.44 5% 4.61 1% 9.28 8.34 11% Ex-US 2.98 2.52 18% 2.71 10% 5.68 5.18 10% API 2.74 3.22 -15% 2.59 6% 5.32 6.28 -15% Total Revenue 16.48 15.95 3% 15

  5. Slide 5: Diversified Therapy Presence

    Diversified Therapy Presence Revenue – Q2 FY25 Revenue – H1 FY25 INR Bn INR Bn Growth: 6% CAGR: 13.1% 5.77 6.09 11.80 1.18 11.01 0.98 9.89 10.29 Animal Health 1.67 1.71 7.21 Acute Specialty 3.07 3.24 Q2FY24 Q2FY25 FY21 FY22 FY23 Axis Title FY24 FY25 Sales Mix - Q2 FY25 Anti Infective Cough & Cold 

  6. Slide 6: Branded Business – Rx driven rankings

    Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS Q2 Q2 BRANDS Q2 Q2 129 0.23 47 FY 25* FY 25 FY 25* FY 25 AZITHRAL 1 29.8 WIKORYL 3 9.9 MAT Sep 24 ALTHROCIN 1 86.7 CLOFF 3 13.1 MAT Sep 23 CRINA-N

  7. Slide 7: High focus therapies

    High focus therapies  Gynecology, Cardiology, Anti Diabetic and Ophthalmology have shown good growth. Q2 FY25 Growth Comparison Therapy APL Market* Gynaecology 8% 7% Gastrointestinal 7% 13% Anti Diabetic 18% 13% Cardiology 11% 15% Ophthalmology 13% -1% *Above market growth are based on respective M

  8. Slide 8: New Launches

    New Launches New launches continue to do well along with promising future launches across key segments. Q2 FY25 Therapy Molecule Brands Launch INR Mn Dydrogesterone / Dydrogesterone SR ISOFIT/ISOFIT SR 2022 187 Gynecology Iron Ferric RICHAR-FCM/TUFEHART 2023 43 Raft Mkt ULGERAFT/EVARAFT/EXCERAFT 202

  9. Slide 9: Animal Health Business

    Animal Health Business Revenue – Q2 FY25 Revenue – H1 FY25 Growth 20% CAGR 25.0% 2,160 1,780 Q2FY24 1,460 1,180 1,170 Q2FY25 980 880 Q2FY24 Q2FY25 FY21 FY22 FY23 FY24 FY25 Sales Mix – Q2 FY25  Operating in Livestock and Poultry and Companion animal market. Antibiotic  Leaders in Hematinic and Anti

  10. Slide 10: Technology transforming business

    Technology transforming business Deployment of Ipads for MR interaction with the Healthcare Medical Professional’s (HMP’s) - Upgrading our scope to communicate medico-marketing content to the HMP for our brands along with an increased time spend during calls. Upgraded to SalesForce platform for In

  11. Slide 11: US Business

    US Business Revenue- Q2 FY25 Revenue – Last 5 years INR Bn INR Bn 4.44 Growth 5% 4.67 21.63 19.76 17.30 16.66 15.72 Q2FY24 Q2FY25 FY20 FY21 FY22 FY23 FY24 Approved ANDAs Injectable 16 Inhalation Derma 2 Well-established US front end with strong customer base 30 8 products launched in Q2FY25. Cumul

  12. Slide 12: Ex-US Business

    Ex-US Business Revenue – Q2 FY25 Revenue – Last 5 years INR Bn INR Bn Growth 18% 2.98 CAGR: 21% 2.52 10.52 8.52 Q2FY24 Q2FY25 7.79 7.75  Robust growth of 18% driven by high demand across the markets 4.97  Ex-US driven by partnership in following key markets - Europe, Canada, Australia, Brazil and

  13. Slide 13: API Business

    API Business Revenue – Q2 FY25 Revenue – Last 5 years INR Bn INR Bn 3.22 De-Growth (-15%) 2.74 CAGR: 15% 12.46 11.66 9.55 9.39 Q2FY24 Q2FY25 7.08 Decline of 15% on YoY basis, on account of the pricing headwinds and low off–take from few selected customers 1 US DMF filed in Q2 FY25. 134 Cumulative

  14. Slide 14: R&D

    R&D Dosage form wise ANDA approval and Launch R&D Capabilities Q2FY25 Dosage Forms Formulation : Vadodara and Hyderabad Approval* Launch OSD 5 4 API : Vadodara and Hyderabad Injectable - Gen 2 1 Bio Centre : Vadodara Injectable - Onco 0 0 Ophthalmology 1 1 Dermatology 1 2 Other 0 0 Total 9 8 *Includ

  15. Slide 15: Yearly Financials

    Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 11.78 62.29 10.53 # 9.61 56.53 7.79 # 6.65 # 6.16 53.93 4.97 # 53.06 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 EBIDTA margin % Capex INR Bn ROCE % 41 * 30 6.87 20 # 4.67 25*# 15 4.12 14 # 3.45 14*# 15 FY21 FY22

  16. Slide 16: Enhancing ESG compliance

    Sustainability Enhancing ESG compliance Commissioned 12 MW Solar park at Bhatpur, Gujarat Targets: Developed 82 Nos. of recharge well and planted 20,000 Trees so far 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) Net-Zero by 2040 16% Reduction (YoY) in To

  17. Slide 17: Strategic Roadmap

    Strategic Roadmap Business Initiatives in FY24 Plan for FY25 • Increased focus on the animal health space with therapy leading products. • Improve depth in the current strength with new launches • Deployment of Ipads for MR interaction with the planned in FY 25 & launches done in FY 24. The India Bu

  18. Slide 18: Company Overview

    ATTEN, — Touching Lives over OY Company Overview

  19. Slide 19: Company at a Glance

    Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,33,000 Team size Field Force 14,500 + 5,200 + Brands Manufacturing facilities 9 198 ANDA filings Net Zero 263 (Sep 30, 2024) 2040 R&D Centres Products in US 2 157

  20. Slide 20: Value Proposition

    Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca

  21. Slide 21: The Journey

    The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved Indian Cardiology, FDA approved API facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facilit

  22. Slide 22: Robust Infrastructure

    Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids July’24 Oncology Oral Solids Mar’24 F2 – Panelav Oncology Injectables Oct’24 F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Mar’23 F4 – Jarod General Oral Soli

  23. Slide 23: Thank you

    For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3681 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com

Alembic Pharmaceuticals — Q2 FY2025 Earnings Presentation on 6ix